Did You Know?

Editor’s Picks

Latest News

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under...

Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021

Detailed results from Phase 2b study of roflumilast foam in scalp and body psoriasis featured in late-breaking oral presentationData demonstrate...

Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis

Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment Efficacy assessments showed a clinically meaningful...

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner...

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives...

error: Content is protected !!